GRCE   $4.38  -1.35% Market Closed After Close 4.5 2.74%

Grace Therapeutics, Inc.
Total Cash 19.41M
totalCashPerShare 1.914
EBITDA -13.27M
Total Debt 0.00
quickRatio 7.618
currentRatio 7.857
Total Revenue
debtToEquity
Revenue/Share
ROA -0.116210006
ROE -0.18556999
grossProfits
freeCashflow -5.58M
operatingCashflow -9.69M
earningsGrowth
revenueGrowth
grossMargins 0.0
ebitdaMargins 0.0
operatingMargins 0.0
profitMargins 0.0
enterpriseValue 12.02M
forwardPE -2.4603174
floatShares 4.65M
sharesOutstanding 10.14M
sharesShort 154.19K
sharesShortPriorMonth 3.86K
dateShortInterest
sharesPercentSharesOut 0.02%
heldPercentInsiders 0.38%
heldPercentInstitutions 0.21%
Short Ratio help_outline 3.84%
shortPercentOfFloat 0.02%
impliedSharesOutstanding
bookValue 5.855
Price To Book help_outline 0.53
earningsQuarterlyGrowth
netIncomeToCommon -11.45M
trailingEps -1.43%
forwardEps -1.26%
enterpriseToEbitda -0.91
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.46 3Q 2024
institutionsCount 15
lastUpdated Nov. 3, 2024, 9:14 a.m.